Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
English Version English Version
  MedUni Wien  trenner  Intranet  trenner  MedUni Wien - Shop  trenner  Universitätsbibliothek  trenner  Universitätsklinikum AKH Wien  trenner
 
Krebsforschung.png
 
 
 
Hauptnavigation
  • Home
  • Mission Statement
    • Chronik
    • 50 Jahre Institut für Krebsforschung
    • Imagevideo: Institut für Krebsforschung
  • Forschung
    • Forschungsschwerpunkte
    • Forschungsgruppen
    • Wissenschaftliche Services - Core Facilities
  • Lehre
    • Vorlesungen und Seminare des Institutes
    • Universitätslehrgang Toxikologie für Postgraduierte
    • PhD Program Inflammation and Immunity
    • PhD Program IPPTO Translational Oncology
    • PhD Programm Malignant Diseases
    • PhD Programm Clinical and Experimental Oncology
  • Kontakt
    • Kontakt
    • Lageplan
 
Forschung / Forschungsschwerpunkte / Sicherheit chemischer Substanzen und Krebsprävention / Gergely Szakacs / Associated Group Leaders
 
Subnavigation
  • Forschungsschwerpunkte
    • Zelluläre und molekulare Tumorbiologie
    • Angewandte und experimentelle Onkologie
    • Sicherheit chemischer Substanzen und Krebsprävention
      • Gergely Szakacs
        • Research Projects
        • Group Members
        • Associated Group Leaders
      • Bettina Grasl-Kraupp
      • Wolfgang Huber
      • Siegfried Knasmüller
      • Teaching
    • Progression und Metastasierung von Tumoren
  • Forschungsgruppen
  • Wissenschaftliche Services - Core Facilities


Inhaltsbereich

 

 

Agnes Csiszar, Senior Postdoc
E-Mail: agnes.csiszar@meduniwien.ac.at
Phone: +43 (0)1 40160 - 57597, 57604
Fax:   +43 (0)1 40160 - 957500

                                   

 

Research Focus:

Metastasis of carcinomas is responsible for more than 80% of cancer-associated death, yet it is still the most poorly understood part of cancer pathogenesis. Interleukin-like EMT inducer (ILEI), also called FAM3C, is one of the secreted factors that regulate tumor progression. It is upregulated in several cancers and its altered subcellular localization is a predictor of poor survival in human breast cancer. We aim to understand the molecular mechanisms of ILEI function and regulation in cancer pathogenesis using cellular and mouse model systems of EMT and tumor progression with direct exploration of findings on primary human clinical samples.

 

Research Projects:

Mechanism and role of ILEI dimerization in tumor progression (supported by FWF stand-alone grant P25834-B23)

Group Members:

 

Barizah Malik, PhD Student
(joint with the group of Prof. Sibilia)
E-Mail: n11745993 [at] students.meduniwien [dot] ac [dot] at
Phone: +43 (0)1 40160 - 57597


Osama Al-Rubaye,
Diploma student
Phone: +43 (0)1 40160-57623

Selected Publications:

Interleukin-like epithelial-to-mesenchymal transition inducer activity is controlled by proteolytic processing and plasminogen-urokinase plasminogen activator receptor system-regulated secretion during breast cancer progression.
Csiszar A
, Kutay B, Wirth S, Schmidt U, Macho-Maschler S, Schreiber M, Alacakaptan M, Vogel GF, Aumayr K, Huber LA, Beug H.
Breast Cancer Res
. 2014 Sep 9; 16(5):433

CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance.
Putz EM, Gotthardt D, Hoermann G, Csiszar A, Wirth S, Berger A, Straka E, Rigler D, Wallner B, Jamieson AM, Pickl WF, Zebedin-Brandl EM, Müller M, Decker T, Sexl V.
Cell Rep. 2013 Aug 15; 4(3):437-44 [in process]

A novel conserved phosphotyrosine motif in the Drosophila fibroblast growth factor signaling adaptor Dof with a redundant role in signal transmission.
Csiszar A
, Vogelsang E, Beug H, Leptin M.
Mol Cell Biol
. 2010 Apr; 30(8):2017-27

Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge.
van Zijl F, Mair M, Csiszar A, Schneller D, Zulehner G, Huber H, Eferl R, Beug H, Dolznig H, Mikulits W.
Oncogene
. 2009 Nov 12; 28(45):4022-33

ILEI requires oncogenic Ras for the epithelial to mesenchymal transition of hepatocytes and liver carcinoma progression.
Lahsnig C, Mikula M, Petz M, Zulehner G, Schneller D, van Zijl F, Huber H, Csiszar A, Beug H, Mikulits W.
Oncogene. 2009 Feb 5; 28(5):638-50

All Publications:

PubmedDatabase

 
Drucken
 
 
© MedUni Wien | Impressum | Nutzungsbedingungen | Datenschutzerklärung | Barrierefreiheit | Kontakt